<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31561542</PMID><DateCompleted><Year>2020</Year><Month>02</Month><Day>11</Day></DateCompleted><DateRevised><Year>2020</Year><Month>02</Month><Day>11</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>19</Issue><PubDate><Year>2019</Year><Month>Sep</Month><Day>26</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Discovery of 3-Arylquinoxaline Derivatives as Potential Anti-Dengue Virus Agents.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">4786</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms20194786</ELocationID><Abstract><AbstractText>We designed and synthesized a series of novel 3-arylquinoxaline derivatives and evaluated their biological activities as potential dengue virus (DENV) replication inhibitors. Among them, [3-(4-methoxyphenyl)quinoxalin-2-yl](phenyl)methanol (<b>19a</b>), [6,7-dichloro-3-(4-methoxyphenyl)quinoxalin-2-yl](phenyl)methanol (<b>20a</b>), and (4-methoxyphenyl)(3-phenylquinoxalin-2-yl)methanone (<b>21b</b>) were found to significantly inhibit the DENV RNA expression in Huh-7-DV-Fluc cells with a potency better than that of ribavirin. Compound <b>19a</b> reduced DENV replication in both viral protein and messenger RNA (mRNA) levels in a dose-dependent manner and exhibited no significant cell cytotoxicity. Notably, compound <b>19a</b> exhibited a half maximal effective concentration (EC<sub>50</sub>) value at 1.29 &#xb1; 0.74 &#x3bc;M. We further observed that the inhibitory effect of <b>19a</b> on DENV replication was due to suppression of DENV-induced cyclooxygenase-2 (COX-2) expression. Docking studies also showed that <b>19a</b> caused hydrophobic interactions at the active sites with Arg29, Glu31, Tyr116, Leu138, Pro139, Lys454, Arg455, and Gln529. The calculated lowest binding energy between the <b>19a</b> and COX-2 was -9.10 kcal/mol. In conclusion, compound <b>19a</b> might be a potential lead compound for developing an anti-DENV agent.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tseng</LastName><ForeName>Chih-Hua</ForeName><Initials>CH</Initials><Identifier Source="ORCID">0000-0001-7392-7104</Identifier><AffiliationInfo><Affiliation>School of Pharmacy, College of Pharmacy, Kaohsiung Medical University, Kaohsiung 807, Taiwan. chihhua@kmu.edu.tw.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Fragrance and Cosmetic Science, College of Pharmacy, Kaohsiung Medical University, Kaohsiung 807, Taiwan. chihhua@kmu.edu.tw.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Drug Development and Value Creation Research Center, Kaohsiung Medical University, Kaohsiung 807, Taiwan. chihhua@kmu.edu.tw.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Research, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan. chihhua@kmu.edu.tw.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacy, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung 801, Taiwan. chihhua@kmu.edu.tw.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Cheng-Ruei</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>School of Pharmacy, College of Pharmacy, Kaohsiung Medical University, Kaohsiung 807, Taiwan. st88036942017@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Kai-Wei</ForeName><Initials>KW</Initials><AffiliationInfo><Affiliation>School of Pharmacy, College of Pharmacy, Kaohsiung Medical University, Kaohsiung 807, Taiwan. dadaking1107@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>09</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011810">Quinoxalines</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.99.1</RegistryNumber><NameOfSubstance UI="D051546">Cyclooxygenase 2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051546" MajorTopicYN="N">Cyclooxygenase 2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003716" MajorTopicYN="N">Dengue Virus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062105" MajorTopicYN="N">Molecular Docking Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056004" MajorTopicYN="N">Molecular Dynamics Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011810" MajorTopicYN="N">Quinoxalines</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">3-arylquinoxaline</Keyword><Keyword MajorTopicYN="N">cyclooxygenase-2</Keyword><Keyword MajorTopicYN="N">dengue virus</Keyword><Keyword MajorTopicYN="N">ribavirin</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>9</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>9</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>9</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>9</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>9</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>2</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31561542</ArticleId><ArticleId IdType="pmc">PMC6801405</ArticleId><ArticleId IdType="doi">10.3390/ijms20194786</ArticleId><ArticleId IdType="pii">ijms20194786</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization and World Meteorological Organization . Atlas of health and climate. World Health Organization and World Meteorological Organization; Geneva, Switzerland: 2012. p. 21. Section 1: infections.</Citation></Reference><Reference><Citation>Halstead S.B. Pathogenesis of dengue: Challenges to molecular biology. Science. 1988;239:476&#x2013;481. doi: 10.1126/science.239.4839.476.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.239.4839.476</ArticleId><ArticleId IdType="pubmed">3277268</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurane I. Dengue hemorrhagic fever with special emphasis on immunopathogenesis. Comp. Immunol. Microbiol. Infect. Dis. 2007;30:329&#x2013;340. doi: 10.1016/j.cimid.2007.05.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cimid.2007.05.010</ArticleId><ArticleId IdType="pubmed">17645944</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalayanarooj S. Clinical manifestations and management of dengue/DHF/DSS. Trop. Med. Health. 2011;39:83&#x2013;87. doi: 10.2149/tmh.2011-S10.</Citation><ArticleIdList><ArticleId IdType="doi">10.2149/tmh.2011-S10</ArticleId><ArticleId IdType="pmc">PMC3317599</ArticleId><ArticleId IdType="pubmed">22500140</ArticleId></ArticleIdList></Reference><Reference><Citation>Low J.G., Ooi E.E., Vasudevan S.G. Current status of dengue therapeutics research and development. J. Infect. Dis. 2017;215:S96&#x2013;S102. doi: 10.1093/infdis/jiw423.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiw423</ArticleId><ArticleId IdType="pmc">PMC5388029</ArticleId><ArticleId IdType="pubmed">28403438</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y.T., Wu Y.H., Tseng C.K., Lin C.K., Chen W.C., Hsu Y.C., Lee J.C. Green tea phenolic epicatechins inhibit hepatitis C virus replication via cycloxygenase-2 and attenuate virus-induced inflammation. PLoS ONE. 2013;8:e54466. doi: 10.1371/journal.pone.0054466.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0054466</ArticleId><ArticleId IdType="pmc">PMC3554764</ArticleId><ArticleId IdType="pubmed">23365670</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu H., Cong J.P., Yu D., Bresnahan W.A., Shenk T.E. Inhibition of cyclooxygenase 2 blocks human cytomegalovirus replication. Proc. Natl. Acad. Sci. USA. 2002;99:3932&#x2013;3937. doi: 10.1073/pnas.052713799.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.052713799</ArticleId><ArticleId IdType="pmc">PMC122626</ArticleId><ArticleId IdType="pubmed">11867761</ArticleId></ArticleIdList></Reference><Reference><Citation>Schr&#xf6;er J., Shenk T. Inhibition of cyclooxygenase activity blocks cell-to-cell spread of human cytomegalovirus. Proc. Natl. Acad. Sci. USA. 2008;105:19468&#x2013;19473. doi: 10.1073/pnas.0810740105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0810740105</ArticleId><ArticleId IdType="pmc">PMC2614784</ArticleId><ArticleId IdType="pubmed">19033472</ArticleId></ArticleIdList></Reference><Reference><Citation>Waris G., Siddiqui A. Hepatitis C virus stimulates the expression of cyclooxygenase-2 via oxidative stress: Role of prostaglandin E2 in RNA replication. J. Virol. 2005;79:9725&#x2013;9734. doi: 10.1128/JVI.79.15.9725-9734.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.79.15.9725-9734.2005</ArticleId><ArticleId IdType="pmc">PMC1181604</ArticleId><ArticleId IdType="pubmed">16014934</ArticleId></ArticleIdList></Reference><Reference><Citation>Jhaveri R., Kundu P., Shapiro A.M., Venkatesan A., Dasgupta A. Effect of hepatitis C virus core protein on cellular gene expression: Specific inhibition of cyclooxygenase 2. J. Infect. Dis. 2005;191:1498&#x2013;1506. doi: 10.1086/429301.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/429301</ArticleId><ArticleId IdType="pubmed">15809909</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin C.K., Tseng C.K., Wu Y.H., Liaw C.C., Lin C.Y., Huang C.H., Chen Y.H., Lee J.C. Cyclooxygenase-2 facilitates dengue virus replication and serves as a potential target for developing antiviral agents. Sci. Rep. 2017;7:44701. doi: 10.1038/srep44701.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep44701</ArticleId><ArticleId IdType="pmc">PMC5357798</ArticleId><ArticleId IdType="pubmed">28317866</ArticleId></ArticleIdList></Reference><Reference><Citation>Saudi M., Zmurko J., Kaptein S., Rozenski J., Neyts J., Van Aerschot A. Synthesis and evaluation of imidazole-4,5- and pyrazine-2,3-dicarboxamides targeting dengue and yellow fever virus. Eur. J. Med. Chem. 2014;87:529&#x2013;539. doi: 10.1016/j.ejmech.2014.09.062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2014.09.062</ArticleId><ArticleId IdType="pmc">PMC4237513</ArticleId><ArticleId IdType="pubmed">25285371</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkatesham A., Saudi M., Kaptein S., Neyts J., Rozenski J., Froeyen M., Van Aerschot A. Aminopurine and aminoquinazoline scaffolds for development of potential dengue virus inhibitors. Eur. J. Med. Chem. 2017;126:101&#x2013;109. doi: 10.1016/j.ejmech.2016.10.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2016.10.008</ArticleId><ArticleId IdType="pubmed">27750144</ArticleId></ArticleIdList></Reference><Reference><Citation>Tseng C.H., Lin C.K., Chen Y.L., Hsu C.Y., Wu H.N., Tseng C.K., Lee J.C. Synthesis, antiproliferative and anti-dengue virus evaluations of 2-aroyl-3-arylquinoline derivatives. Eur. J. Med. Chem. 2014;79:66&#x2013;76. doi: 10.1016/j.ejmech.2014.03.074.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2014.03.074</ArticleId><ArticleId IdType="pubmed">24727241</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J.C., Tseng C.K., Lin C.K., Tseng C.H. Discovery of novel diarylpyrazolylquinoline derivatives as potent anti-dengue virus agents. Eur. J. Med. Chem. 2017;141:282&#x2013;292. doi: 10.1016/j.ejmech.2017.10.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2017.10.001</ArticleId><ArticleId IdType="pubmed">29031073</ArticleId></ArticleIdList></Reference><Reference><Citation>Radwan A.A., Abdel-Mageed W.M. In silico studies of quinoxaline-2-carboxamide 1,4-di-n-oxide derivatives as antimycobacterial agents. Molecules. 2014;19:2247&#x2013;2260. doi: 10.3390/molecules19022247.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules19022247</ArticleId><ArticleId IdType="pmc">PMC6271882</ArticleId><ArticleId IdType="pubmed">24566302</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariq S., Somakala K., Amir M. Quinoxaline: An insight into the recent pharmacological advances. Eur. J. Med. Chem. 2018;143:542&#x2013;557. doi: 10.1016/j.ejmech.2017.11.064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2017.11.064</ArticleId><ArticleId IdType="pubmed">29207337</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira J.A., Pessoa A.M., Cordeiro M.N., Fernandes R., Prud&#xea;ncio C., Noronha J.P., Vieira M. Quinoxaline, its derivatives and applications: A State of the Art review. Eur. J. Med. Chem. 2015;97:664&#x2013;672. doi: 10.1016/j.ejmech.2014.06.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2014.06.058</ArticleId><ArticleId IdType="pubmed">25011559</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonz&#xe1;lez M., Cerecetto H. Quinoxaline derivatives: A patent review (2006--present) Expert Opin. Ther. Pat. 2012;22:1289&#x2013;1302. doi: 10.1517/13543776.2012.724677.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/13543776.2012.724677</ArticleId><ArticleId IdType="pubmed">22971178</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi L., Hu W., Wu J., Zhou H., Zhou H., Li X. Quinoxalinone as a privileged platform in drug development. Mini. Rev. Med. Chem. 2018;18:392&#x2013;413. doi: 10.2174/1389557517666171101111134.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1389557517666171101111134</ArticleId><ArticleId IdType="pubmed">29090665</ArticleId></ArticleIdList></Reference><Reference><Citation>Jampilek J. Recent advances in design of potential quinoxaline anti-infectives. Curr. Med. Chem. 2014;21:4347&#x2013;4373. doi: 10.2174/0929867321666141011194825.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/0929867321666141011194825</ArticleId><ArticleId IdType="pubmed">25312209</ArticleId></ArticleIdList></Reference><Reference><Citation>Tseng C.H., Chen Y.R., Tzeng C.C., Liu W., Chou C.K., Chiu C.C., Chen Y.L. Discovery of indeno[1,2-b]quinoxaline derivatives as potential anticancer agents. Eur. J. Med. Chem. 2016;108:258&#x2013;273. doi: 10.1016/j.ejmech.2015.11.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2015.11.031</ArticleId><ArticleId IdType="pubmed">26686931</ArticleId></ArticleIdList></Reference><Reference><Citation>Kano S., Shibuya S., Yuasa Y. Synthesis of quinoxaline derivatives through condensation of 1,2-diaminobenzenes with &#x3b2;-keto sulfoxides. J. Heterocycl. Chem. 1980;17:1559&#x2013;1561. doi: 10.1002/jhet.5570170741.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jhet.5570170741</ArticleId></ArticleIdList></Reference><Reference><Citation>Lou S.J., Xu D.Q., Shen D.F., Wang Y.F., Liu Y.K., Xu Z.Y. Highly efficient vinylaromatics generation via iron-catalyzed sp3 C-H bond functionalization CDC reaction: A novel approach to preparing substituted benzo[&#x3b1;]phenazines. Chem. Commun. 2012;48:11993&#x2013;11995. doi: 10.1039/c2cc36708d.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/c2cc36708d</ArticleId><ArticleId IdType="pubmed">23128502</ArticleId></ArticleIdList></Reference><Reference><Citation>Roehm N.W., Rodgers G.H., Hatfield S.M., Glasebrook A.L. An improved colorimetric assay for cell proliferation and viability utilizing the tetrazoliumsalt XTT. J. Immunol. Methods. 1991;142:257&#x2013;265. doi: 10.1016/0022-1759(91)90114-U.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-1759(91)90114-U</ArticleId><ArticleId IdType="pubmed">1919029</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xe1;nchez-Linares I., P&#xe9;rez-S&#xe1;nchez H., Cecilia J.M., Garc&#xed;a J.M. High-throughput parallel blind virtual screening using BINDSURF. BMC Bioinform. 2012;13:S13. doi: 10.1186/1471-2105-13-S14-S13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-13-S14-S13</ArticleId><ArticleId IdType="pmc">PMC3504923</ArticleId><ArticleId IdType="pubmed">23095663</ArticleId></ArticleIdList></Reference><Reference><Citation>Rego N., Koes D. 3Dmol.js: Molecular visualization with WebGL. Bioinformatics. 2015;31:1322&#x2013;1324. doi: 10.1093/bioinformatics/btu829.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btu829</ArticleId><ArticleId IdType="pmc">PMC4393526</ArticleId><ArticleId IdType="pubmed">25505090</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>